News | May 28, 2025
Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Akums invested Rs. 272 crore in capital expenditure during FY25
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
For the full year FY25, net profit soared 12x to Rs 345 crore
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
